The Desmoid Tumor Research Foundation

April 2017

Pazopanib, a promising option for the treatment of aggressive fibromatosis.

Author Information

Aisha Miah,Charlotte Benson,Christina Messiou,Han Hsi Wong,Helen Hatcher,Ian Judson,Robin L Jones,Shane Zaidi,Winette T A van der Graaf,Zoltan Szucs

aSarcoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London bDepartment of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge cThe Institute of Cancer Research, Sutton, UK.

Publication

Summary

We reviewed our bi-institutional (Royal Marsden Hospital, Cambridge University Hospitals) experience with the tyrosine kinase inhibitor pazopanib in the treatment of progressing DT/AF. Eight patients with DT/AF were treated with pazopanib at Royal Marsden Hospital and Cambridge University Hospitals between June 2012 and June 2016. The median age of the patients was 37.5 (range: 27-60) years. The median duration of pazopanib treatment was 12 (range: 5-22) months and for three patients the treatment is ongoing. Only one patient experienced intolerable toxicity (grade 3 hypertension) leading to early treatment discontinuation. In our series of patients with DT/AF, pazopanib demonstrated important activity both in terms of symptom control (75%) and absence of radiological progression (100%). Results of ongoing confirmatory trials are eagerly awaited.

View Abstract